Pregnancy is accompanied by larger high density lipoprotein particles and compositionally distinct subspecies

John T. Melchior1*, Debi K. Swertfeger3*, Jamie Morris1, Scott E. Street1, Carri R. Warshak1, Jeffrey A. Welge3, Alan T. Remaley6, Janet M. Catov7, W. Sean Davidson6, and Laura A. Woollett1*

1Department of Pathology and Laboratory Medicine, University of Cincinnati Medical School, Cincinnati, OH, USA; 2Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA; 3Division of Biomedical Informatics, Children's Hospital Research Foundation, Cincinnati, OH, USA; 4Department of Obstetrics and Gynecology and 5Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati Medical School, Cincinnati, OH, USA; 6Lipoprotein Metabolism Section, Cardio-Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; and 7Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine and Magee Women's Research Institute, Pittsburgh, PA, USA

Abstract  Pregnancy is accompanied by significant physiological changes, which can impact the health and development of the fetus and mother. Pregnancy-induced changes in plasma lipoproteins are well documented, with modest to no impact observed on the generic measure of high density lipoprotein (HDL) cholesterol. However, the impact of pregnancy on the concentration and composition of HDL subspecies has not been examined in depth. In this prospective study, we collected plasma from 24 nonpregnant and 19 pregnant women in their second trimester. Using nuclear magnetic resonance (NMR), we quantified 11 different lipoprotein subspecies from plasma by size, including three in the HDL class. We observed an increase in the number of larger HDL particles in pregnant women, which were confirmed by tracking phospholipids across lipoproteins using high-resolution gel-filtration chromatography. Using liquid chromatography-mass spectrometry (LC-MS), we identified 87 lipid-associated proteins across size-speciated fractions. We report drastic shifts in multiple protein clusters across different HDL size fractions in pregnant females compared with nonpregnant controls that have major implications on HDL function. These findings significantly elevate our understanding of how changes in lipoprotein metabolism during pregnancy could impact the health of both the fetus and the mother.

Supplementary key words dyslipidemia • nuclear magnetic resonance spectroscopy • lipoprotein • proteomics • mass spectrometry • pregnancy • lipoprotein size • lipoprotein metabolism • phospholipids • LC-MS

A successful pregnancy is defined by a gestational length of 39–40 weeks with birthweights of 2.5–4.0 kg and no complications (1, 2). During pregnancy, the maternal body undergoes numerous physiological changes to ensure optimal conditions for healthy fetal growth and development (3). For example, there are dramatic shifts in plasma lipid homeostasis with major elevations in maternal plasma triglyceride and cholesterol levels (3–5) that can increase upward of 50% in this relatively short time span. Circulating lipoproteins are the vehicles responsible for distributing triglyceride and cholesterol to maternal tissues and the fetus through the placenta (6–10). Increased circulating levels of triglyceride and cholesterol, specifically cholesterol carried by low density lipoproteins (LDL), are typically associated with increased risks for development of coronary heart disease; however, these increases are considered healthy during pregnancy. The role of high density lipoproteins (HDL) in pregnancy is less clear and often overlooked as HDL-cholesterol (HDL-C) levels are unchanged in most pregnancies.

Lipoproteins are mostly studied for their role in lipid transport and maintenance of tissue lipid homeostasis and thus are usually defined based on measures of triglyceride and cholesterol content. Recent studies have shown that specific subclasses of lipoproteins, primarily of HDL, participate in a number of other critical physiological functions, many of which are involved in ensuring a healthy pregnancy. HDL is now appreciated for its role in regulation of lipid metabolism, hemostasis, immune response, inflammation, complement activation, metal binding, and vitamin transport (11). In addition to this functional diversity, HDL is also highly compositionally heterogeneous with over 200 different proteins potentially associated with these particles (https://homepages.uc.edu/~davidswm/HDLproteome.html, Davidson, WS). Not surprisingly, the documented function of many of these HDL-associated proteins...
overlaps with many of the aforementioned functional pathways of HDL. Indeed, we have shown that these proteins are in disequilibrium on plasma HDL and tend to segregate into compositional subspecies (12–16), which likely perform distinct functions.

Most studies on HDL in pregnancy have focused on HDL-C, which lack the information on the changes associated with HDL subspecies and function. The goal of this study was to examine changes in lipoprotein subspecies between pregnant and nonpregnant women. We used nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry (LC-MS) to characterize changes in the lipoprotein proteomic signature in pregnant women compared with nonpregnant controls. These findings significantly aid our current understanding of lipoprotein metabolism during pregnancy and suggest that more detailed compositional studies on lipoprotein subspecies could provide keen insights into pathologies associated with adverse outcomes such as preterm birth.

MATERIALS AND METHODS

Study demographics

Women in the current study were enrolled to determine the impact of pregnancy on lipoprotein composition. Women aged 18–40 years who were in general good health were eligible. Pregnant women were recruited from the UC Health—Hoxworth Center after their initial doctor visit; samples were collected between 18 and 24 weeks of gestation based on time elapsed since last menstrual cycle. Nonpregnant women were recruited by word of mouth and fliers placed around the UC College of Medicine. Blood (30 ml) was collected after an overnight fast, after informed consent, at the Schubert Research Center (SRC) at Cincinnati Children's Hospital Medical Center (CCHMC) using K2EDTA as the anticoagulant to obtain plasma immediately following blood collections. The height, weight, and birthdate of the women were self-reported (nonpregnant) or obtained from medical records (pregnant). BMI was calculated from the height and weight of the women at the time of the study. A total of 24 nonpregnant women and 19 pregnant women participated in the study. The protocol was approved by the Institutional Review Board of the University of Cincinnati and follows the Declaration of Helsinki principles.

Lipid, apolipoprotein, lipoprotein sizing, and HDL lipid composition

NMR (Vantera® Clinical Analyzer) was used to measure lipid distribution, lipoprotein size, and both particle and apolipoprotein concentrations from plasma of nonpregnant and pregnant women as previously described (17). Particles within each lipoprotein class were further resolved to report concentrations of small, medium, and large subfractions using the LP4 algorithm (18). Total and esterified cholesterol (FUJIFILM Medical Systems USA, Inc, VA) and triglyceride (MedTest Dx, MI) concentrations were measured in HDL samples isolated by ultracentrifugation (d 1.063–1.210 g/ml) from fresh plasma as previously described (19).

Removal of APOB-containing lipoproteins and gel filtration chromatography

In a separate analysis, APOB-containing lipoproteins were precipitated from plasma by heparin and magnesium chloride (20). Briefly, plasma from nonpregnant and pregnant women was incubated with heparin and magnesium chloride for 30 min on ice, centrifuged at 1,500g for 30 min, and supernatant was carefully removed for analysis. HDL size subspecies were also separated by gel filtration chromatography from a subset of three nonpregnant and three pregnant women as previously described (13). Equivalent volumes of plasma (354 µl) from each individual were applied to three superdex 200 gel filtration columns (10/300 GL; GE Healthcare) in series. Plasma was eluted in standard tris buffer (150 mM NaCl, 10 mM Tris-HCl, 1 mM EDTA, 0.02% Azide) at 0.3 ml/min and 1.5 ml fractions were collected for analysis. Phospholipid elution patterns were generated by measuring lipid concentrations in each lipoprotein fraction (Phospholipids C and Cholesterol E, Wako).

Preparation and analysis of samples by LC-MS

APOB-depleted plasma and the HDL subspecies in each fraction spanning fractions 20–30 were incubated with calcium silicate hydrate (lipid-removal agent, LRA) to sequester lipid-associated proteins as previously described (13, 20). The bound lipoproteins were washed thoroughly with 10 mM ammonium bicarbonate (pH = 8.0), and proteins were digested directly off the LRA by incubation with sequencing-grade trypsin overnight at 37 °C with gentle shaking. Digested peptides were collected and reduced with 10 mM DTT for 30 min at 42 °C followed by alkylation with 40 mM iodoacetamide for 30 min at room temperature in the dark. Peptides were dried under vacuum and stored at −20 °C until ready for analysis by LC-MS. Peptides were reconstituted in 15 µl solvent A (formic acid/H2O 0.1/99.9, v/v) and 5 µl was loaded onto a reverse phase column (ACQUITY UPLC C18, Waters) maintained at 40 °C with an Infinity 1290 autosampler and HPLC (Agilent). Peptides were eluted at 0.1 ml/min using a mobile phase gradient from 5% solvent B (formic acid/acetonitrile 0.1/99.9, v/v) to 32% solvent B over 60 min to 50% solvent B over 2 min. The column was cleaned by ramping the mobile phase gradient to 90% solvent B for 10 min followed by re-equilibration of the column at 5% solvent B for 10 min. Peptides were introduced to the mass spectrometer using a Jet Stream source (Agilent) and identified and fragmented as previously described (21). Precursors were limited to acquisition of ions with charge states of +2 for 2+ and +3 and required a minimum of 1,500 counts. Each cycle acquired the 20 most intense precursors, which were fragmented with a variable collision energy (CE) dependent on the precursor mass-to-charge (m/z) ratio: CE = k* (m/z) + b, with a slope (k) of 3 and an offset (b) of 2 for 2+ ions and −2 for 3+ ions. MS/MS spectra were acquired until at least 45,000 total counts were collected or a maximum accumulation time of 0.33 s.

Mass spectrometry data analysis

The LC-MS data for all samples were analyzed using the bioinformatic pipeline shown in supplemental Fig. S1. First, mascot generic files (MGFs) were generated from the raw data files using MassHunter Qualitative Analysis Software.
(v B07.00, Agilent). MS/MS peaks were limited to the top 150 peaks by height and precursors were limited to a maximum assigned charge state of 3+. Peptide spectral data was matched against the UniProt KP/Swiss-prot protein knowledgebase for Homo sapiens (version: release 2017_11, date: 12-20-2017, entries: 20,319) using the Mascot search engine (v 2.2.07). Trypsin was used to generate peptides and data was constrained to allow for a maximum of three missed cleavages, fixed modification of carbamidomethylation, and a variable modification of oxidation with a peptide tolerance of 35 ppm and MS/MS tolerance of 0.6 Da. Scaffold (v 4.3.4) was employed for MS/MS peptide validation using X! Tandem (2010.12.01, subset of 1,590 entries). Identified proteins and peptides were constrained to 99.9% and 95.0% probability, respectively, and protein inclusion required identification of at least two unique peptides. The list of proteins was further constrained to only including proteins that showed up in the same fraction across all three patients within an experimental cohort. For example, protein A had to meet the minimum identification thresholds in fraction N of either all three nonpregnant or all three pregnant females to be included in the list. A final list of 92 proteins were selected and integrated into a FASTA file. As raw Agilent files are incompatible with MaxQuant, the Agilent data files were first formatted to mzML files with 32-bit binary encoding precision, write index, and TPP compatibility for all MS levels using the Vendor Algorithm. The mzML files were further formatted into mzXML files with forced MaxQuant compatibility using TOPPAS file converter. The final mzXML files and custom fasta file were used to perform label-free quantification (LFQ) using MaxQuant (22). Samples were further processed by exporting the final proteomic LFQ data into Perseus (23) for final analysis.

Cholesterol efflux

Cholesterol efflux was measured using APOB-depleted plasma as described (24) with minor modifications. Briefly, RAW 264.7 macrophages were grown to confluence and incubated with media containing 1.0 μCi/ml [1,2-3H(N)]-cholesterol. After extensive washing, media containing equal volumes of sample (40 μl) ±0.3 mM 8-bromo-cAMP were incubated with the macrophages for 8 h. In all experiments, media alone and media containing 10 μg/ml of plasma APOA1 by protein were included as quality controls. Cholesterol efflux was measured by harvesting the media, filtering with a 0.45 μm filter, and quantifying radiolabeled cholesterol by scintillation counting. Each subfraction from each donor was run in triplicate, and the percent efflux was calculated by dividing the number of counts in the media by the total internalized counts per well (determined from the media-only treated cells). Data are presented in an equal volume basis and where stated, the percent efflux was normalized by total phospholipid concentration of the APOB-depleted samples measured enzymatically.

Statistics

Data are presented as averages ± SEM. Demographics (maternal age, maternal BMI) were analyzed by student's t-tests. Sizing for each lipoprotein was analyzed using two-way repeated measures ANOVA (between-subjects factor is pregnancy and within-subject factor is particle size) using BMI as an interacting covariate (i.e., effects of pregnancy on the particle size distribution were allowed to possibly depend on BMI). We analyzed lipid and apolipoprotein concentrations by one-way ANOVA with BMI as a covariate. Proteinic differences were determined in total HDL by ANOVA with multiple-testing adjustment to achieve a maximum false discovery rate (FDR) of 5% to generate a q-value. FDR-adjusted significance levels were computed for pairwise comparisons for all proteins, and we note those that met the FDR-corrected threshold (q < 0.05).

RESULTS

Demographics and plasma lipids

Nonpregnant and pregnant women were similar in age with pregnant women having greater BMI than nonpregnant women (Table 1, supplemental Fig. S2). Body weights of pregnant women were obtained at the time of blood draw, which ranged from 18 to 24 weeks gestation. A summary of the measures from the standard lipid panel in nonpregnant and pregnant women is shown in Table 1. Total cholesterol concentrations were ~20% greater in the pregnant compared with nonpregnant controls with most of the elevation observed in concentrations of LDL-C. We observed a parallel increase in plasma APOB concentrations of pregnant women with no significant differences in plasma triglyceride or triglyceride-rich lipoprotein (TRL-C) concentrations. Taken together, this suggests that the elevation in total cholesterol during pregnancy was due to increased number of LDL particles as opposed to increased cholesterol content of the LDL fraction. Indeed, there were strong correlations between APOB and LDL-C concentrations (r = 0.95, P < 0.0001) and APOB and plasma cholesterol concentrations (r = 0.93, P < 0.001). Conversely, plasma HDL and APOA1 concentrations were similar between groups. There was no relationship between any of these parameters and BMI, with BMI as either a main effect or as an interaction with pregnancy.

| TABLE 1. Clinical characteristics of study participants |
|---------------------------------|-----------------|------------------|
| Characteristics                | Non-pregnant (N=24) | Pregnant (N=19) | P |
| Age (years)                    | 31.7 ± 13        | 28.9 ± 13        | 0.153 |
| BMI                            | 24.7 ± 13        | 20.9 ± 17*       | 0.004 |
| Gestational age (weeks)        | 21.7 ± 0.7       | 22.7 ± 12.4*     | 0.039 |
| Plasma cholesterol (mg/dl)     | 188± ± 7.2       | 227.4 ± 12.4*    | 0.039 |
| TRL-C (mg/dl)                  | 18.9 ± 19        | 23.6 ± 2.8       | 0.266 |
| LDL-C (mg/dl)                  | 103.7 ± 5.4      | 134.3 ± 10.5*    | 0.017 |
| HDL-C (mg/dl)                  | 65.5 ± 31        | 60.6 ± 2.9       | 0.892 |
| Plasma triglyceride (mg/dl)    | 83.8 ± 9.0       | 94.0 ± 7.3       | 0.207 |
| APOB (mg/dl)                   | 77.7 ± 4.3       | 100.2 ± 6.5*     | 0.022 |
| APOA1 (mg/dl)                  | 157.2 ± 4.8      | 168.8 ± 6.9      | 0.750 |

Abbreviations: APOA1, apolipoprotein A-I; APOB, apolipoprotein-B100; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TRL-C, triglyceride-rich lipoprotein cholesterol.

Values represent mean ± standard error of mean. P-values derived by Student’s t-tests (demographics) and lipids and apolipoproteins by one-way ANOVA with BMI as a covariate. Bold represents significant differences.
Lipoprotein size and particle number

Recent studies have shown that advanced lipid analysis of lipoprotein subspecies using NMR spectroscopy can provide additional insights into individual health beyond those of standard plasma lipid panels (25–27). Using NMR spectroscopy and the LP4 algorithm, we performed an analysis of lipoprotein subspecies in the plasma of nonpregnant and pregnant women (Table 2). The sizes of TRL and LDL were similar in all women while plasma HDL in pregnant women was significantly larger compared with nonpregnant women.

The lipoprotein populations were further subdivided into size-defined particle subclasses as previously reported (28). One of the subspecies measured are classified as TRL, which encompass a broad range of traditional larger-sized lipoprotein subclasses such as intermediate density lipoproteins (IDL, 25–35 nm), VLDL (30–80 nm), and even some chylomicrons (75–1,200 nm), though these women were fasted. We found total TRL particle concentrations were similar between both groups of females (Fig. 1, top). The very small particles accounted for a majority of the TRL fraction, and there was a 40% increase in the very small particles in the pregnant compared with nonpregnant females. There were no differences in the amounts of small and medium particles between groups. Concentrations of large and very large TRL particles were very low and not different between the nonpregnant and pregnant females.

The concentration of LDL particles was the highest among the APOB-containing lipoproteins measured (Fig. 1), which is reflected by its strong correlation to APOB concentration ($r = 0.97, P < 0.001$). Plasma LDL particles were significantly higher in pregnant females (Fig. 1, middle), which were driven primarily by the increase the amount of small LDL particles, which were 2-fold higher in pregnant women compared with their nonpregnant counterparts. There was no difference in concentrations of medium or large LDL particles between nonpregnant and pregnant females though medium particles trended toward being decreased in pregnant females ($P = 0.088$).

Plasma HDL is the most heterogeneous of the lipoprotein subfractions. The concentration of total HDL particles was the highest among all the lipoprotein subclasses with the number of HDL particles over 10-fold higher than LDL and TRL combined (note HDLP is reported as μmol/L). Similar to plasma HDL-C, no differences were observed in HDL particle number between nonpregnant and pregnant females (Fig. 1, bottom). Most of the HDL in both groups was comprised of small particles, which were no different between groups. In contrast, pregnant females exhibited significantly less medium HDLs and more large HDLs compared with nonpregnant women.

HDL speciation and composition

The compositional diversity of HDL with regard to their proteomic signature has garnered significant attention as of late (16, 20, 29, 30). We investigated compositional differences in the APOB-depleted plasma from nonpregnant and pregnant females by identifying and quantifying relative protein abundance using LC-MS and MaxQuant (22). Plasma was first depleted of APOB-containing lipoproteins, then the remaining lipid-associated complexes were adsorbed to a phospholipid binding resin to eliminate free proteins. Despite this material being composed almost entirely of HDL, we are careful to refer to this as “APOB-depleted plasma” and not “HDL” as it technically contains a small amount of other lipid-containing vesicles. Using shotgun proteomics we identified 70 total proteins across nonpregnant and pregnant females; no unique proteins were found in either group. All of the

| Subfraction | Diameter Range (nm) | NP Diameter | P Diameter | NP Concentration | P Concentration |
|-------------|---------------------|-------------|------------|-----------------|----------------|
| TRLP        | 24–240              | 45.6 ± 1.4  | 46.0 ± 1.6 | 103.4 ± 1.01    | 114.0 ± 17.8   |
| Very small  | 24–29               |             |            | 522 ± 7.7      | 913 ± 14.4***  |
| Small       | 30–36               |             |            | 36.4 ± 7.2     | 30.3 ± 6.8     |
| Medium      | 37–49               |             |            | 126 ± 19       | 16.8 ± 29      |
| Large       | 50–89               |             |            | 21 ± 0.7       | 20 ± 0.6       |
| Very large  | 90–240              |             |            | 0.1 ± 0.0      | 0.1 ± 0.0      |
| LDL         | 19–23               | 21.1 ± 0.1  | 20.9 ± 0.1 | 1356.0 ± 65.3  | 1807.4 ± 116.1*|
| Small       | 19–20               |             |            | 647.3 ± 74.1   | 1292 ± 84.0**  |
| Medium      | 20–21               |             |            | 3002 ± 73.3    | 1207 ± 71.5    |
| Large       | 21–23               |             |            | 4085 ± 46.5    | 394.7 ± 80.5   |
| HDLP        | 7.5–13              | 9.4 ± 0.1   | 9.7 ± 0.1* | 228 ± 0.5      | 229 ± 0.5      |
| Small       | 7.4–7.8             |             |            | 129 ± 0.6      | 138 ± 0.6      |
| Medium      | 8.7–9.5             |             |            | 63 ± 0.6       | 21 ± 0.4***    |
| Large       | 10–12               |             |            | 3.6 ± 0.5      | 61 ± 0.4***    |

Abbreviations: HDP, high density lipoprotein particle; LDLP, low density lipoprotein particle; NP, nonpregnant; P, pregnant; TRLP, triglyceride-rich lipoprotein particle.

Concentration is reported at μmol/L for TRLP and LDLP and μmol/L for HDLP.

Values represent mean ± standard error of mean of 24 and 19 individuals in the nonpregnant and pregnant groups, respectively.

Asterisks denote statistically significant differences at *$P < 0.05$; **$P < 0.01$; ***$P < 0.001$. 

![Image](image-url)
identified proteins in the current study have been previously reported to be associated with HDL based on the HDL proteome watch (https://homepages.uc.edu/~davidswm/HDLproteome.html, Davidson, WS). We went on to perform LFQ of the identified proteins to determine if pregnancy had any impact on their relative abundance in the APOB-depleted samples. We identified significant changes in 25 HDL-associated proteins, which are expressed as fold difference in LFQ intensity in pregnant versus nonpregnant females in Fig. 2. A total of 14 proteins were enriched in pregnant females with the biggest and most significant differences in pregnancy zone protein (PZP), angiotensinogen (AGT), ceruloplasmin (CP), complement factor B (CFB), and alpha-1B-glycoprotein (A1BG). Conversely, we observed a decrease in 11 proteins in pregnant females with the largest differences or most significant differences in N-acetylmuramoyl-L-alanine amidase (PGLYRP2), apolipoprotein A-IV (APOA4), and albumin (ALB). A full list of proteins and LFQ intensities for the APOB-depleted samples can be found in supplemental Table S1.

We next investigated whether the proteomic differences observed in the total HDL between nonpregnant and pregnant females were specific to distinct HDL subspecies. As the NMR technique for quantitating lipoprotein subspecies is solely analytical, we utilized an orthogonal approach for separating lipoproteins by size using high-resolution gel filtration chromatography. This separation has the added advantage of providing...
material for additional biochemical characterizations of particle composition. Whole plasma was applied to three superflo 200 columns in series, which results in a broad HDL peak that resolves different HDL subspecies (fractions 20–30) and a single peak where VLDL and LDL coelute between fractions 15 and 19. The isolations were performed on a subset of three nonpregnant and three pregnant females with matched BMI. The HDL-sized fractions were collected and subjected to LC-MS analysis after isolating lipid-containing species from comigrating plasma proteins by LRA (see Methods) (13).

We went on to perform proteomic analysis on lipid-containing particles spanning the HDL-size range (fractions 20–30). In total (i.e., all fractions considered together), we found that speciation of HDL by gel filtration resulted in the identification of 17 additional unique proteins that were not identified in total plasma samples subjected to APOB-depletion described above (Fig. 4A). Nonetheless, when we examined the relationship between the common proteins identified between the two methods, we observed an excellent correlation in protein abundance between the two isolation procedures (Fig. 4B). This supports the notion that the subset of females randomly selected from each group is highly representative of the larger clinical cohort. The LFQ intensities of each protein identified across gel filtration fractions were imported into Perseus, which was used to determine the protein z-score. The z-score is a normalization reflective of the increase compared with pregnant women was more modest using gel filtration chromatography. These seemingly disparate measures between techniques likely result from the different entities being measured; NMR quantifies particle number based on the methyl groups on lipids to give a total while phospholipid concentration is determined on the fractionated plasma isolated using gel filtration. In the latter case, phospholipid values can represent an enrichment of phospholipid in the particles and/or an increase in the number of phospholipid-containing particles in the fraction.

![Fig. 2. Impact of pregnancy on the HDL proteome. HDL was isolated by APOB-depletion and binding to LRA. Proteins were analyzed by LC-MS and abundance quantified using MaxQuan as described. Bars represent the ratio of the mean abundance of the protein in pregnant (N = 19) to nonpregnant women (N = 24) and error bars represent standard error across samples. Asterisks denote level of significance at *p < 0.05, **p < 0.01 or ***p < 0.001.](image)

![Fig. 3. Impact of pregnancy on lipoprotein distribution. Plasma from nonpregnant and pregnant females was separated using gel filtration chromatography. Phospholipid concentration was measured in each fraction. Based on previously published information (86), the TRL/LDL particles (fractions 15–19) were 19–240 nm, large HDL particles (fractions 20–22) were 10.2–12 nm, medium HDL particles (fractions 23–24) were 8.7–10.2 nm, and small HDL particles (fractions 25–26) were 7.4–8.6 nm. Fractions 27–30 contained lipid-poor proteins. Bars represent standard deviation of n = 3 patients in each group. * denote statistically significant differences between nonpregnant and pregnant groups at P < 0.05 as determined by Student's t test.](image)
number of standard deviations above or below the mean of a given protein across all fractions in both the nonpregnant and pregnant females. A hierarchical clustering of proteins was performed based on the Euclidian distance between the averages of the protein abundance pattern across the fractions.

The protein clusters and accompanying heat map of the z-score are shown in Fig. 5 with HDL fractions in nonpregnant females on the left and pregnant females on the right. We set a relative Euclidean distance of <3.0, which resulted in 25 total protein clusters that are colored in the dendogram. We observed striking changes in the abundance of several of these clusters in specific HDL fractions in pregnant females. The most apparent increase was found in the eight-member cluster containing PZP, FGG, FBB, FN1, FGA, A2M, HPR, and APOL1 in fraction 20. We also observed more modest increases in three-member protein clusters PSG1, PSG4, and SHBG in fraction 25 and GC, SERPINF1 and SERPINA1 in fraction 30. Conversely, there were clear decreases in the two-member cluster of HBB and HP and three-member cluster of KLKB1, IGHA1, and IGHG3 in fractions 20 and 22, respectively. Decreases in larger clusters such as the eight-member cluster of C2, ECM1, APOA2, IGHG1, IGHG2, IGKV-III, IGKC, and IGLL5 in fraction 25 and four-member cluster of RBP4, APOA4, TTR, and ALB in fraction 30 were also observed. A full list of proteins and LFQ intensities for the fractionated samples can be found in supplemental Table S2.

Cholesterol efflux

Given the striking differences in the HDL species and particle composition observed in both the APOB-depleted plasma and fractionated plasma, we wanted to determine if these differences impacted HDL function. To do this, we measured the cholesterol efflux capacity on equal volumes of APOB-depleted plasma from pregnant and nonpregnant females incubated with RAW 264.7 macrophages that were stimulated with cAMP (Fig. 6). We found that APOB-depleted plasma from pregnant subjects exhibited a modest, but significant increase capacity to efflux cholesterol from cells compared with nonpregnant counterparts. Given the differences in particle number and phospholipid concentration observed in the NMR and gel filtration analyses, we sought to determine if efflux was due to active transport (i.e., ABCA1-mediated) or passive diffusion due to phospholipid differences. To do this, efflux was normalized to total phospholipid content loaded in the assay. As shown in Fig. 6, the differences in efflux between APOB-depleted plasma from nonpregnant and pregnant women were no different after normalization indicating that the observed differences in nonnormalized data are likely due to the changes in the aqueous diffusion pathway.

DISCUSSION

NMR, high-resolution gel filtration chromatography, and mass spectroscopy were used to examine the impact of pregnancy on lipoprotein subspecies concentrations and compositions, with a specific focus on the proteomic makeup of the particles. The impact of pregnancy on cholesterol concentrations was consistent with previous reports, which show increases in total LDL-C but modest to no change in HDL-C. The observed 30% increase in APOB concentrations in the
plasma of pregnant women is in line with past studies (31–33) and is likely due to the estradiol-induced increase of APOB production (34, 35). We found the increase was specific to very small TRL and small LDL particles in the pregnant females. The increase in these populations is thought to be due to decreased hepatic uptake due to decreased enrichment in APOE (36) and decreased affinity to the LDL receptor (37). Small, dense LDL is associated with heart disease, however, mostly because it has the greatest extent of lipid modifications, which are often proinflammatory (38). How these features may be related to pregnancy is not known. While the proteomic composition and function of these particles were out of the scope of the current study, their relationship with pregnancy warrants further investigation given their critical role in lipid transport and metabolism.

Deeper investigation of the HDL subspecies revealed that pregnancy had a profound impact on the quantity of the distinct particle subtypes; an important observation as HDLs’ diverse functionality depends on both the size and proteomic composition of the particles. NMR measures show that pregnancy resulted in an increase in the number of large HDL at the expense of medium-sized particles, a shift that was more pronounced after analysis by high-resolution gel filtration chromatography. While several factors likely contribute to this increase in particle size, multiple studies have demonstrated...
increased triglyceride content in HDL isolated from pregnant women suggesting that changes in the neutral lipid core content could be driving the observed differences (39–41). Although the current study was focused on the proteomic composition of the particles, we did observe a trend (P = 0.07) toward increased triglyceride content of a subset of HDL isolated by ultracentrifugation in pregnant versus nonpregnant women consistent with these reports (data not shown). Previous studies have reported that these triglyceride-rich HDLs are associated with increased levels and activity of CETP (39–41) while others report the triglyceride enrichment results from decreased hepatic lipase activity (33, 42, 43). Interestingly, we observed an increase in APOA2 associated with HDL in larger particles in fraction 22 (Fig. 5, supplemental Table S2), which can sequester liberated hepatic lipase thereby inhibiting its activity (44, 45). We suspect these particles result from a combination of changes in several pathways as part of a programmed metabolic response designed to satisfy the energy-requiring needs of the fetus (46, 47). Indeed, multiple cell types in the placenta express receptors important for the uptake of HDL and maternal-fetal transport of some of the HDL cargo (6, 7, 47–52).

While lipid uptake by the placenta is critical for healthy embryo development during pregnancy, too much lipid, especially sterol, in any cell or tissue can be deleterious. Here we observed that maternal HDLs exhibit a modest, but significant increase in their ability to efflux cholesterol. However, despite the large proteomic changes observed in the study, it appears this increase is due entirely to increases in the large, phospholipid-enriched particles that are present in the pregnant females. Our group has previously reported the acute appearance of large HDLs after weight loss surgery similar to those observed in pregnant women here (53). Consistent with our measures, that study showed an increase in cholesterol efflux capacity in APOB-depleted plasma from the same patients associated with the appearance of those particles. While we did not specifically measure the cholesterol efflux capacity of the large particles in the current study, previous work from our group (54) strongly indicates that the increased phospholipid content we see with the rise in the large particle population in pregnancy is likely driving the increase efflux capacity observed in the APOB-depleted plasma of pregnant women. As mentioned above, this would suggest that the rise of these particles is playing an important role in lipid homeostasis at the maternal-fetal interface.

Pregnancy also resulted in profound changes in several proteins associated with different plasma HDLs. In APOB-depleted plasma, many of the proteins enriched on HDL are known to inhibit proteases (PZP, AGT, SERPINA1) and play major roles in the complement pathway (CFB, C9, CFH, and C3). Surprisingly, proteins that were attenuated in APOB-depleted plasma of pregnant women are known to inhibit inflammation (ALB, PON1, APOA4). We also found that two trypanosome lytic factor proteins, which are constitutively innate immune effectors, APOL1 and haptoglobin-related protein (HPR) (55), were enriched in pregnant HDL. Taken together, this suggests a compositionally altered HDL in pregnancy that could potentially modulate inflammation and mediate innate immunity. This is important as pregnancy results in a complex inflammatory response where inflammation is greater in early pregnancy to allow for implantation of the fetus, but decreases mid-pregnancy to dampen the immune-modulated rejection of the semiallogeneic fetus (56). Left unchecked, inflammation can result in adverse pregnancy outcomes, including preterm birth and preeclampsia (57–63). Given the major role of HDL in the inflammatory response (64), the observed changes in these proteins suggest they may play major roles in toggling that response in pregnant women. Pregnancy also resulted in increases in proteins important in autophagy (fibrinogens, macroglobulin, and haptoglobin) and vitamin A binding and transport (TTR, RBP4), which appear mostly localized to the large HDL. Autophagy and vitamin transport have both been associated with various aspects of maintaining a healthy pregnancy at the level of the placenta and implantation and at systemic inflammation (57, 60, 65–70).

**Fig. 6. Cholesterol efflux of APOB-depleted plasma from pregnant and nonpregnant women.** Plasma from pregnant and nonpregnant women was APOB-depleted and their ability to mediate cholesterol efflux was determined on RAW 364.7 macrophages treated with 8-bromo-cAMP. Cholesterol efflux was determined using equal volumes of APOB-depleted plasma (raw, left) and normalized to total phospholipid content in APOB-depleted fractions (normalized, right). Bars represent averages ± standard error for n = 22 nonpregnant women and n = 19 pregnant women. Asterisks denote level of significance at P < 0.05 as determined using a Tukey-Kramer HSD.
In summary, pregnancy alters HDL particle size and a number of protein clusters on distinct HDLs. It is likely these compositional changes alter the particle function in several metabolic pathways important for maternal and fetal health. Understanding the molecular details of HDL composition and function in normal pregnancy is critical for identifying potential alterations in HDLs associated with adverse outcomes, especially those associated with excessive inflammation, such as preterm deliveries or preeclampsia. These adverse outcomes affect about \( \approx 10\% \) and \( \approx 4\% \) of pregnancies, respectively, and have severe long- and short-term consequences for the mother and infant (71, 72). Our findings suggest that monitoring these more informative molecular markers could provide essential metabolic readouts on fetal and maternal health during pregnancy. These measures could also provide insights into the mechanisms responsible for increased development of cardiovascular disease in women with preterm deliveries or preeclampsia (73–77).

**Strengths and limitations**

The main strength of this study was that we examined the impact of pregnancy on lipoprotein subspeciation, including concentrations and compositions of the various subspecies of HDL. Previous studies have shown rather unremarkable changes in generic markers of HDL (i.e., HDL-C) likely deincentivizing deeper dives into the role of HDL in pregnancy. Our work unequivocally shows that, while overall cholesterol levels and even particle numbers do not change in HDL, the quality, and likely functionality, of those particles may shift dramatically. We suggest that this opens the door to understanding how changes in HDL functionality might impact adverse outcomes, as suggested by previous studies (33, 36, 78–81). The main weakness of our study design was its cross-sectional nature. Ideally, and hopefully pursued in future studies, a longitudinal study can be done in which HDL profiling is done in women prior to, during (several time points), and after pregnancy. This would factor out inevitable differences between women allowing for temporal differences to be monitored within each subject. In addition, racial information was unavailable for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that pregnancy is critical for identifying potential alterations in HDLs associated with adverse outcomes, especially those associated with excessive inflammation, such as preterm deliveries or preeclampsia. These adverse outcomes affect about \( \approx 10\% \) and \( \approx 4\% \) of pregnancies, respectively, and have severe long- and short-term consequences for the mother and infant (71, 72). Our findings suggest that monitoring these more informative molecular markers could provide essential metabolic readouts on fetal and maternal health during pregnancy. These measures could also provide insights into the mechanisms responsible for increased development of cardiovascular disease in women with preterm deliveries or preeclampsia (73–77).

**Strengths and limitations**

The main strength of this study was that we examined the impact of pregnancy on lipoprotein subspeciation, including concentrations and compositions of the various subspecies of HDL. Previous studies have shown rather unremarkable changes in generic markers of HDL (i.e., HDL-C) likely deincentivizing deeper dives into the role of HDL in pregnancy. Our work unequivocally shows that, while overall cholesterol levels and even particle numbers do not change in HDL, the quality, and likely functionality, of those particles may shift dramatically. We suggest that this opens the door to understanding how changes in HDL functionality might impact adverse outcomes, as suggested by previous studies (33, 36, 78–81). The main weakness of our study design was its cross-sectional nature. Ideally, and hopefully pursued in future studies, a longitudinal study can be done in which HDL profiling is done in women prior to, during (several time points), and after pregnancy. This would factor out inevitable differences between women allowing for temporal differences to be monitored within each subject. In addition, racial information was unavailable for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co- no effect of race on LDL or HDL sizing, though race will affect the results as a previous study showed for most of the women in this study. It is unlikely that race will affect the results as a previous study showed no effect of race on LDL or HDL sizing, though possibly VLDL sizing, in pregnant women (81) or co-
3. Herrera, E., and Ortega-Senovilla, H. (2010) Maternal lipid metabolism during normal pregnancy and its implications to fetal development. *Clim. Lipidol.* 5, 899–911.

4. Grimes, S. B., and Wild, R. (2017) Effect of pregnancy on lipid metabolism and lipoprotein levels. In *Endokrynologie: K. R. Feingold*, B. Anawalt, A. Boyce, G. Chrousos, W. de Herder, K. Dhatariya, K. Dungan, A. Grossman, J. Hershman, G. Kaltas, J. Holtden, S. Kalra, G. Kaltas, C. Koch, P. Kopp, et al., editors. MDText.com, Inc., South Dartmouth, MA.

5. Herrera, E., and Desoye, G. (2016) Maternal and fetal lipid metabolism under normal and gestational diabetic conditions. *Horm. Mol. Biol. Clin. Investig.* 26, 109–127.

6. Wadsack, C., Hammer, A., Levak-Frank, S., Desoye, G., Kozarsky, K. F., Hirschmugl, B., Sattler, W., and Malle, E. (2003) Selective cholesteryl ester uptake from high density lipoprotein by human first trimester and term villous trophoblast cells. *Placenta* 24, 141–143.

7. Burke, K. T., Colvin, P. L., Mylatt, L., Graf, G. A., Schroeder, F., and Woollert, L. A. (2009) Transport of maternal cholesterol to the fetus is affected by maternal plasma cholesterol concentrations in the Golden Syrian hamster. *J. Lipid Res.* 50, 1146–1155.

8. Wadsack, C., Bess, G., Roche, A. F., Aebi, E., Rebourcet, R., Mordon, F., and Cedard, L. (1987) Ultrastructural visualization of the internalization of low density lipoprotein by human placental cells. *Histochemistry* 87, 457–464.

9. Shah, A. S., Tan, L., Long, J. L., and Davidson, W. S. (2015) Proteomic diversity of high density lipoproteins our emerging understanding of its importance in lipid transport and beyond. *J. Lipid Res.* 54, 2837–2845.

10. Davidson, W. S., Gamgani, R. A., Silva, D., Chantepie, S., Lagor, W., and Shah, A. S. (2015) The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth. *Diabetes* 64, 2958–2967.

11. Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., and Ridker, P. M. (2009) Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation* 119, 951–959.

12. Kontush, A., Lindahl, M., Lhomme, M., Calabresi, L., Chapman, M. J., and Davidson, W. S. (2015) Structure of HDL: Particle subclasses and molecular components. *Handb. Exp. Pharmacol.* 224, 3–51.

13. Jimenez, D. M., Pocovi, M., Ramon-Cajal, J., Romero, M. A., Martinez, H., and Grande, F. (1988) Longitudinal study of plasma lipids and lipoprotein cholesterol in normal pregnancy and gestational diabetes mellitus. *Gynecol. Obstet. Invest.* 25, 158–164.

14. Alvarez, J. J., Montelongo, A., Iglesias, A., Lasuncion, M. A., and Herrera, E. (1996) Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postpartum lipases during gestation in women. *J. Lipid Res.* 37, 299–308.

15. Schaefer, E. J., Foster, D. M., Zech, L. A., Lindgren, F. T., Brewer, H. B., Jr., and Levy, R. I. (1983) The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. *J. Clin. Endocrinol. Metab.* 57, 262–267.

16. Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., and Sacks, F. M. (1991) Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. *N. Engl. J. Med.* 325, 116–120.

17. Silliman, K., Shore, V., and Forte, T. M. (1994) Hypertriglyceridemia during late pregnancy is associated with the formation of small dense low-density lipoproteins and the presence of large buoyant high-density lipoproteins. *Metabolism* 43, 1003–1011.

18. Ray, R. P., Pellegrini, J., Hines, J., and Yeung, W. N. (1989) NMR measurement of LDL particle number using the Vantera Clinical Analyzer. *Clin. Biochem.* 23, 203–210.

19. Daumerie, C., Woollert, L. A., and Dietschy, J. M. (1992) Fatty acids regulate hepatic low density lipoprotein receptor activity through redistribution of intracellular cholesterol pools. *Proc. Natl. Acad. Sci. U. S. A.* 89, 10797–10801.

20. Davidow, W. S., Heink, A., Sexsmith, H., Melchior, J. T., Gordon, S. M., Kuklenyik, Z., Woollert, L., Barr, J. R., Jones, J. L., Toth, C. A., and Shah, A. S. (2016) The effects of apolipoprotein B depletion on HDL subclasses composition and function. *J. Lipid Res.* 57, 674–686.

21. Gonzalez Fernandez-Nino, S. M., Smith-Moritz, A. M., Chan, L. J., Adams, P. D., Heazlewood, J. L., and Petzold, C. J. (2015) Standard flow liquid chromatography for shotgun proteomics in bioenergy research. *Front. Bioeng. Biotechnol.* 3, 44.

22. Coxe, L., and Mann, M. (2015) MassViewer enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367–1372.

23. Tyanova, S., and Cox, J. (2018) Perseus: A bioinformatics platform for integrative analysis of proteomics data in cancer research. *In Cancer Systems Biology Methods* 1. L. von Seelen, editor. Humana Press, New York, NY, 133–148.

24. Melchior, J. T., Street, S. E., Andraski, A. B., Futardo, J. D., Sacks, F. M., Shute, R. L., Greve, E. I., Swertfeger, D. K., Li, H., Shah, A. S., Lu, L. J., and Davidson, W. S. (2017) Apolipoprotein A-I alters the proteome of human lipoproteins and enhances cholesterol efflux from ARCA1. *J. Lipid Res.* 58, 1374–1385.

25. Rosenson, R. S., Brewer, H. B., Jr., Chapman, M. J., Fazio, S., Hussain, M. M., Kontush, A., Krauss, R. M., Otros, J. D., Remaley, A. T., and Schaefer, E. J. (2011) HDL measure, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. *Clin. Chem.* 57, 392–410.

26. Otros, J. D. (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. *Clin. Lab.* 48, 171–180.

27. Mora, S., Otros, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., and Ridker, P. M. (2009) Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation* 119, 951–959.

28. Otros, J. D., Jeyarajah, E. J., and Cromwell, W. C. (2002) Measurement issues related to lipoprotein heterogeneity. *Am. J. Cardiol.* 90, 221–226.

29. Gordon, S. M., Hofmann, S., Askew, D. S., and Davidson, W. S. (2011) High density lipoprotein: its not just about lipid transport anymore. *Trends Endocrinol. Metab.* 22, 9–15.

30. Shah, A. S., Tan, L., Long, J. L., and Davidson, W. S. (2010) Proteomic characterization of human high density lipoprotein fractionated by gel filtration chromatography, *J. Proteome Res.* 10, 5239–5249.
39. Iglesias, A., Montelongo, A., Herrera, E., and Lasuncion, M. A. (1994) Changes in cholesteryl ester transfer protein activity during normal gestation and postpartum. *Clin. Biochem.* 27, 63–68

40. Silliman, K., Tall, A. K., Kretchmer, N., and Forte, T. M. (1993) Unusual high-density lipoprotein subclass distribution during late pregnancy. *J. Lipid Res.* 32, 1592–1599

41. Royle, C., Mandy, S. G., Burrell, R. H., P. Henriksen, T., and Lekv, T. (2021) Low CETP activity and unique composition of large VLDL and small HDL in women giving birth to small-for-gestational age infants. *Sci. Rep.* 11, 6213

42. Kinnunen, P. K., Unnerus, H. A., Ranta, T., Ehnholm, C., Nikkila, E. A., and Sepaia, M. (1980) Activities of post-heparin plasma lipoprotein lipase and hepatic lipase during pregnancy and lactation. *Eur. J. Clin. Invest.* 10, 469–474

43. Rouhani, N., Young, E., Chatterjee, C., and Sparks, D. L. (2008) HDL composition regulates displacement of cell surface-bound hepatic lipase. *Lipids.* 43, 793–804

44. Mowrz, H. O., Patsch, J. R., Gotto, A. M., Jr., and Patsch, W. (1996) Apolipoprotein A-I influences the substrate properties of human HDL2 and HDL3 for hepatic lipase. *Atheroscler. Thromb. Vasc. Biol.* 16, 755–762

45. Boucher, J., Ramsamy, T. A., Braschi, S., Sahoo, D., Neville, T. A., and Sparks, D. L. (2004) Apolipoprotein A-I regulates HDL stability and affects hepatic lipase association and activity. *J. Biol. Chem.* 279, 21393–21398

46. Herrera, E., and Ortega-Senovilla, H. (2014) Lipid metabolism during pregnancy and its implications for fetal growth. *Curr. Pharm. Biotechnol.* 15, 24–31

47. Woollett, L. A. (2001) The origins and roles of cholesterol and fatty acids in the fetus. *Curr. Opin. Lipidol.* 12, 305–312

48. Bartha, J. L., Fernandez-Deudero, A., Bugatto, F., Fajardo-Estrada, M. F., and Cubillo, E. A., and Candirotta-Davies, T. (2015) Expression and immunlocalisation of the endocytic receptors megalin and cubulin in the human yolk sac and placenta across gestation. *Placenta.* 34, 1005–1009

49. Hammad, S. M., Stefansson, C., Twal, W. O., Drake, C. J., Fleming, P., Remaley, A., Brewer, H. B., Jr., and Argraves, W. S. (1999) Cubulin, the endocytic receptor for intrinsic factor-vitamin B12 complex, mediates high-density lipoprotein holoparticle endocytosis. *Proc. Natl. Acad. Sci. U. S. A.* 96, 10158–10163

50. Hatzopoulos, A. K., Rigotti, A., Rosenberg, R. D., and Krieger, M. (1998) Temporal and spatial pattern of expression of the HDL receptor SR-B1 during murine embryogenesis. *J. Lipid Res.* 39, 495–508

51. Gao, O., Garcia, C. K., Wyne, K. L., Shultz, R. A., Parker, K. L., and Cao, G., Garcia, C. K., Wyne, K. L., Shultz, R. A., Parker, K. L., and Hubs, H. H. (1997) Structure and localization of the human gene encoding SR-BI/CLA-1; Evidence for transcriptional control by steroidalogenic factor-1. *J. Biol. Chem.* 272, 33068–33076

52. Xu, S., Laccotripe, M., Huang, X., Rigotti, A., Zannis, V. I., and Krieger, M. (1997) Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective cholesterol uptake. *J. Lipid Res.* 38, 1289–1298

53. Davidson, W. S., Inge, T. H., Sexsmith, H. L., Heink, A., Elder, D., Hui, D. Y., Melchior, J. T., Kelesidis, T., and Shah, A. S. (2017) Weight loss surgery in adolescents corrects high-density lipoprotein subtypes and their function. *Int. J. Obes. (Lond).* 41, 83–89

54. Swerfeger, D. K., Li, H., Rebolhol, S., Zhu, X., Shah, A. S., Davidson, W. S., and Lu, L. J. (2017) Mapping atheroprotective functions and related proteins/lipoprotein subtypes in size fractionated human plasma. *Cell Metab.* 16, 680–693

55. O'Toole, J. F., Bruggemann, L. A., Madhavan, S., and Sedor, J. R. (2017) The cell biology of APOL1. *Semin. Nephrol.* 37, 538–545

56. Mo, G., Aido, P., and Alvero, A. B. (2017) The unique immunoregulation. *Curr. Opin. Lipidol.* 28, 755–762

57. Romero, R., Dey, S. K., and Roberts, J. M. (2015) Preeclampsia: Syndrome or disease? *Curr. Hypertens. Rep.* 17, 83

58. Munissant, M. B., Kilpatrick, S., Eastwood, J. A., Robbins, W. A., Accortt, E. E., Wei, J., Shufelt, C. L., Droeing, L. V., and Merz, C. N. B. (2018) Association of spontaneous preterm delivery and future maternal cardiovascular disease. *Circulation.* 137, 865–871

59. Gato, J. M., Sh Adler, G., Bullen, B. I., Barrias-Mitchell, E. J. M., and Holzman, C. (2019) Women with preterm birth have evidence of subclinical atherosclerosis a decade after delivery. *J. Womens Health.* 28, 621–627

60. Bartha, J. L., Fernandez-Deudero, A., Bugatto, F., Fajardo-Exposito, M. A., Gonzalez-Gonzalez, N., and Hervas-Vivasconca, B. (2012) Inflammation and cardiovascular risk in women with preterm labor. *J. Womens Health.* 21, 643–648

61. Leon, L. J., McCarthy, F. P., Direk, K., Gonzalez-Izquierdo, A., Prieto-Merina, D., Casas, J. P., and Chappell, L. (2019) Pre-eclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records. A CALIBER study. *Circulation.* 140, 1050–1060

62. Thorp, J. M., Edwards, J. W., Frasier, A., Lawlor, D. A., and Gato, J. M. (2014) Pregnancy characteristics and women’s future cardiovascular health: An undervalued opportunity to improve women’s health? *Epidemiol. Rev.* 36, 57–70

63. Grace, M. R., Vladutiu, C. J., Nethery, R. C., Siega-Riz, A. M., Manuck, T. A., Herring, A. H., Savitz, D., and Thorp, J. T. (2018) Lipoprotein particle concentration measured by nuclear magnetic resonance spectroscopy is associated with gestational age at delivery: a prospective cohort study. *BJOG.* 125, 895–903

64. Zeljkovic, A., Vekic, J., Spasic, V., Jelic-Ivanovic, Z., Spasojevic-Kalinmanovska, V., Gojkovic, T., Ardalic, D., Mandic-Markovic, V., Cerovic, N., and Mikovic, Z. (2013) Changes in LDL and HDL subclasses in normal pregnancy and associations with birth weight, birth length and head circumference. *Matern. Child Health J.* 17, 556–565

65. Thorp, J. M., Rice, M. M., Harper, M., Klebanoff, M., Sorokin, Y., Varner, M. W., Wapner, R. J., Caritis, S. N., Iams, J. D., Peaceman, A. M., Mercer, B. M., Sciscione, A., Rouse, D. J., Ramin, S. M., Anderson, G. B., et al. (2017) Advanced lipoprotein measures and recurrent preterm birth. *Am. J. Obstet. Gynecol.* 219, 342.e1–342.e7

66. Gato, J. M., Mackey, R. H., Scifres, C. M., Bertole, M., and Simmons, H. N. (2017) Lipoprotein heterogeneity early in pregnancy and preterm birth. *Am. J. Perinatol.* 34, 1326–1332

67. Urbina, E. M., McCoy, C. E., Gao, Z., Khoury, P. R., Shah, A. S., Davidson, W. S., and Kubilus, T. R. (2017) Lipoprotein particle number and size predict vascular structure and function better than traditional lipids in adolescents and young adults. *J. Clin. Lipidol.* 11, 1023–1031
83. El Khoudary, S. R., Brooks, M. M., Thurston, R. C., and Matthews, K. A. (2014) Lipoprotein subclasses and endogenous sex hormones in women at midlife. *J. Lipid Res.* **55**, 1498–1504

84. Scifres, C. M., Catov, J. M., and Simhan, H. N. (2014) The impact of maternal obesity and gestational weight gain on early and mid-pregnancy lipid profiles. *Obesity* **22**, 932–938

85. Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., Pérez, E., Uszkoreit, J., Pfeuffer, J., Sachsenberg, T., Yilmaz, S., et al. (2019) The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucleic Acids Res.* **47**, D442–D450

86. Davidson, W. S., Heink, A., Sexmith, H., Dolan, L. M., Gordon, S. M., Otvox, J. D., Melchior, J. T., Elder, D. A., Khoury, J., Geh, E., and Shah, A. S. (2017) Obesity is associated with an altered HDL subspecies profile among adolescents with metabolic disease. *J. Lipid Res.* **58**, 1916–1923